Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• B cell chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoproliferative disorder.
• Prognosis in CLL varies significantly, influenced by genetic factors such as immunoglobulin heavy chain variable (IgV(H)) gene mutations.
• Unmutated IgV(H) is associated with poorer survival outcomes compared to mutated IgV(H).

Purpose of the Study:

• To identify novel gene expression markers for predicting CLL progression.
• To compare the prognostic value of identified genes with the established ZAP70 marker.
• To explore gene expression patterns associated with IgV(H) mutation status in early-stage CLL.

Main Methods:

• Gene expression profiling using high-density microarrays in 36 early-stage CLL patients.
• Differential gene expression analysis based on IgV(H) mutation status and BCL6 mutations.
• Functional profiling using KEGG and gene ontology terms to analyze coordinated gene expression changes.

Main Results:

• Approximately 150 differentially expressed genes were identified based on IgV(H) mutation status; no significant differences were found for BCL6 mutations.
• Functional analysis revealed distinct KEGG and gene ontology terms associated with CLL subgroups.
• CRY1, LPL, CD82, and DUSP22 were validated as differentially expressed genes with prognostic potential, showing performance comparable or superior to ZAP70.

Conclusions:

• IgV(H) mutation status is a significant driver of gene expression differences in CLL.
• CRY1, LPL, CD82, and DUSP22 represent promising novel prognostic biomarkers for CLL.
• These markers may offer improved prediction of disease progression compared to current markers like ZAP70.